Drug intelligence / Profile preview

banlangen + modified yin qiao san

Development stage
Unknown
Lead developer
Guangzhou Baiyunshan Pharmaceutical Holdings
Administration
Oral
01

Overview

This is a combination of two traditional Chinese medicine (TCM) herbal formulas: - **Banlangen** (板蓝根, Isatis root): A widely used TCM herb known for its antiviral, anti-inflammatory, and immune-modulating properties. It is primarily used to clear heat and resolve fire toxicity in the body. Banlangen is most often derived from the dried root of Isatis indigotica or Isatis tinctoria and has been shown in studies to inhibit virus absorption into host cells and regulate immune responses. It is commonly used for early-stage colds, sore throat, tonsillitis, fever, mumps, pharyngitis, laryngitis, erysipelas and other conditions associated with 'heat' or viral infections[6][8][10]. - **Modified Yin Qiao San** (加味银翘散): An adaptation of the classical formula Yin Qiao San (银翘散), which was originally formulated in 1798 for early-stage febrile diseases caused by wind-heat pathogens. The core ingredients include Jin Yin Hua (Lonicera flower), Lian Qiao (Forsythia fruit), Niu Bang Zi (Arctium seed), Bo He (Mint leaf), Dan Zhu Ye (Lophatherum leaf), Jing Jie (Schizonepeta herb/flower) among others[1][2]. Modifications may add or substitute herbs based on specific symptoms such as cough or conjunctivitis[5]. The formula acts mainly by clearing heat toxins from the body surface and throat while supporting immune defense against upper respiratory tract infections. The combination of Banlangen with a modified version of Yin Qiao San aims to enhance antiviral effects—Banlangen provides strong direct antiviral action while Modified Yin Qiao San addresses wind-heat invasion symptoms such as sore throat and fever. This combined approach is commonly used in China for prevention or treatment at the onset of viral respiratory illnesses including influenza-like illnesses.

Other names
ban lan gen + modified yin qiao sanisatis root + modified yin qiao san板蓝根 + 加味银翘散
02

Targets

Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on banlangen + modified yin qiao san.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on banlangen + modified yin qiao san.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call